The Internet has recently circulated news about the Coronary vaccine production base of Chinese pharmaceutical dealer Kangshino's crown disease.It is reported that the company's internal employees have confirmed the matter and said that "at the end of last year, the latest to the beginning of this year, there was no work to work."
According to daily economic news reports, a notification recently circulated on the Internet shows that Kangshino on the Kangshino Crown Diseases Vaccine "" Due to changes in the external market environment, it was decided to suspend the production line from April 4th from April 4th.Production, the deadline is about 180 days. "The notice also said that the company will "keep a small amount of necessary personnel who maintain the basic operation of the company during the adjustment of the production plan. Other personnel do not need to work in the job."
The employee of Yahaangxino confirmed the authenticity of the above notice to the Daily Economic News, and pointed out that the company held a meeting on Monday (April 3) and announced that it would be suspended for six months.The standards pay for employees. As for the subsequent labor contract compensation plan, the company's leaders are still discussing. Tomorrow (April 4) should not have many people to work. "
The employee revealed that Kangshino is basically in a state of suspension and only maintains basic operations.He also said that the signs of "suspending production" of Shangyao Kangnuo have emerged from the end of last year to early this year."At the end of last year, the latest to the beginning of this year, there was no positive work to work, so I was consumed like this.The employee of Yao Kangnano disclosed that his department should have about 80 employees. At present, there are only about 10 people from the job.
It is reported that Kangshino is a coronary vaccine production base jointly invested by Shanghai Pharmaceutical, Kangxino and Shanghai Biomedical Industry Equity Investment Fund in 2021.The company's equity structure is 49.8%of Kangshino's shares, Shanghai Pharmaceutical subsidiaries Shanghai Three -dimensional Biotechnology Co., Ltd. holds 48.9%, and Shanghai Biomedical Industry Equity Fund Partnership (Limited Partnership) holds 1.24%.
Since the beginning of 2022, Kangshino is used to produce Kangxino's crown disease vaccine Ksa; in October 2022, the medicine Kangshino was equipped with inhaled vaccine production lines and 1The production capacity of 100 million doses inhaled with coronary disease.
